Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06566443 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Honokiol in Early-Stage Resectable Non-Small Cell Lung Cancer

StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 11 months later Aug 2026 → Aug 2027
See other at-risk trials from The Methodist Hospital Research Institute

Record History

  1. Primary completion pushed from Aug 2026 to Aug 2027 Completion pushed from Aug 2027 to Aug 2028 · Eligibility criteria expanded, about 18 words · Publications: details revised at 22 of 23 entries Show 3 more changesShow less
    • Completion pushed from Aug 2027 to Aug 2028
    • Eligibility criteria expanded, about 18 words
    • Publications: details revised at 22 of 23 entries
  2. Start date: Nov 8, 2024 to Feb 13, 2025v4
  3. Eligibility criteria shortened, about 3 wordsv3 See this version in full on ClinicalTrials.gov ↗
  4. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Aug 2024 to Nov 8, 2024 · Site details revisedv2 Show 2 more changesShow less
    • Start date changed from estimate of Aug 2024 to Nov 8, 2024
    • Site details revised
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a Phase I Trial evaluating the safety of the dietary supplement honokiol for lung cancer chemoprevention. Female or male patients aged 18 years, or older, with early stage lung cancer who have been scheduled for curative surgery will be eligible for participation in the study. The study will only enroll patients with stage I lung cancers less than 4 cm, given the recent approval of neoadjuvant chemotherapy and nivolumab for stage IB tumors \> 4 cm. Approximately, 15 patients will be enrolled in the study. They will take the study drug, honokiol, for 2 weeks prior to the surgery. The primary endpoint will be the Maximum Tolerated Dose (MTD) of honokiol.
Trial Details
NCT Number NCT06566443
Lead Sponsor The Methodist Hospital Research Institute
Conditions Carcinoma, Non-Small-Cell Lung
Enrollment 15 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov